Scholars Central

Conference abstractPublished 4 Jul 2019

Perspectives in post marketing research

Authors: Deepa Arora

CLINEXEL Life Sciences Pvt Ltd, India

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Post marketing research includes Post Marketing Surveillance (PMS) studies and Drug Utilization Studies (DUS). PMS involves systematic monitoring of medications while they are used in clinical practice. Monitoring of medications while used in routine clinical practice is way different from the controlled settings of premarketing trials, in which study conditions are rigorously controlled. While, randomized clinical trials, which minimize variability, are useful for assessing the efficacy of a drug, they may not inform on the effects of a drug after it has been released for use in the general population. PMS studies can also provide valuable information on the use of drugs in special patient populations. Usually itâ??s not possible to obtain such information from premarketing studies. Requirement for planned post marketing research provides an opportunity for the continued focus on the benefit risk profile of an approved drug, as well as conduct well planned studies in special populations. Although the importance of DUS has been well recognized, still DUS studies are not being planned as extensively as they should be. This presentation will focus on the importance of post marketing research, the value that it adds, the areas where improvisation is desired and regulatory authority and pharmaceutical industries perspective. Recent Publications 1. Haque A, Daniel S, Maxwell T, Boerstoel M (2017). Postmarketing Surveillance Studies-An Industry Perspective on Changing Global Requirements and Implications. Clin Ther. 2017 Apr;39(4):675-685. 2. Spelsberg Angela, Prugger Christof, Doshi Peter, Ostrowski Kerstin, Witte Thomas, Hüsgen Dieter et al. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies BMJ 2017; 356 :j337 3. Real-World Evidence from https://www.evidera.com/wp-content/uploads/2018/10/09-New-Trends-in-Drug- Safety_Fall2018.pdf 4. Engel, P., Almas, M. F., De Bruin, M. L., Starzyk, K., Blackburn, S., and Dreyer, N. A. (2017) Lessons learned on the design and the conduct of Postâ?�Authorization Safety Studies: review of 3 years of PRAC oversight. Br J Clin Pharmacol, 83: 884â?? 893. doi: 10.1111/bcp.13165. 5. Harugeri, A., Shastri, V., & Patel, C. (2017). Deriving meaningful insights from clinical trial and postmarketing safety data: Perspectives from India. Perspectives in clinical research, 8(2), 68-72.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Formulation Science & Bioavailability.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Formulation Science & Bioavailability
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Deepa Arora”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels